Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743804 · ClinicalTrials.gov registry record · Phase 3
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT04743804 is a Phase 3 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04743804, a Phase 3 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.
Interventions
- OTHER Placebo
- BIOLOGICAL Ravulizumab
- OTHER Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743804
The ClinicalTrials.gov registry entry for NCT04743804 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04743804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04743804 about?
NCT04743804 is a clinical study titled "Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger". This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. ...
What is the current status of trial NCT04743804?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2021-06-29. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT04743804?
The interventions under investigation include: Placebo (OTHER), Ravulizumab (BIOLOGICAL), Best Supportive Care (OTHER).
Who is sponsoring clinical trial NCT04743804?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.